BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23529305)

  • 1. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis.
    Liliac L; Carcangiu ML; Canevari S; Căruntu ID; Ciobanu Apostol DG; Danciu M; Onofriescu M; Amălinei C
    Rom J Morphol Embryol; 2013; 54(1):17-27. PubMed ID: 23529305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of PAX8 and WT1 Immunostaining in Confirming the Ovarian Origin of Metastatic Carcinoma in Serous Effusion Specimens.
    Zhao L; Guo M; Sneige N; Gong Y
    Am J Clin Pathol; 2012 Feb; 137(2):304-9. PubMed ID: 22261458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas.
    Nonaka D; Chiriboga L; Soslow RA
    Am J Surg Pathol; 2008 Oct; 32(10):1566-71. PubMed ID: 18724243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
    McKnight R; Cohen C; Siddiqui MT
    Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of WT1 and PAX8 in the epithelial tumours of Malaysian women with ovarian cancer.
    Rhodes A; Vallikkannu N; Jayalakshmi P
    Br J Biomed Sci; 2017 Apr; 74(2):65-70. PubMed ID: 28367736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
    Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
    Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
    Boyd C; McCluggage WG
    Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors.
    Wang M; Ma H; Pan Y; Xiao W; Li J; Yu J; He J
    Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):280-7. PubMed ID: 24992169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serous carcinoma of the ovary with squamous differentiation: a case report and a literature review.
    Roberts DE; Lombard CM
    Int J Gynecol Pathol; 2013 Sep; 32(5):459-63. PubMed ID: 23896710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
    Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
    Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
    Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study.
    Tacha D; Zhou D; Cheng L
    Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):293-9. PubMed ID: 21285870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive analysis of PAX8 expression in human epithelial tumors.
    Laury AR; Perets R; Piao H; Krane JF; Barletta JA; French C; Chirieac LR; Lis R; Loda M; Hornick JL; Drapkin R; Hirsch MS
    Am J Surg Pathol; 2011 Jun; 35(6):816-26. PubMed ID: 21552115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
    Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX8 and PAX2 immunostaining facilitates the diagnosis of primary epithelial neoplasms of the male genital tract.
    Tong GX; Memeo L; Colarossi C; Hamele-Bena D; Magi-Galluzzi C; Zhou M; Lagana SM; Harik L; Oliver-Krasinski JM; Mansukhani M; Falcone L; Hibshoosh H; O'Toole K
    Am J Surg Pathol; 2011 Oct; 35(10):1473-83. PubMed ID: 21934480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor.
    Zhao C; Bratthauer GL; Barner R; Vang R
    Am J Surg Pathol; 2007 Sep; 31(9):1378-86. PubMed ID: 17721194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAX8 expression in uterine adenocarcinomas and mesonephric proliferations.
    Yemelyanova A; Gown AM; Wu LS; Holmes BJ; Ronnett BM; Vang R
    Int J Gynecol Pathol; 2014 Sep; 33(5):492-9. PubMed ID: 25083965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: a comprehensive comparison.
    Ozcan A; Liles N; Coffey D; Shen SS; Truong LD
    Am J Surg Pathol; 2011 Dec; 35(12):1837-47. PubMed ID: 21989345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy.
    Wang Y; Wang Y; Li J; Yuan Z; Yuan B; Zhang T; Cragun JM; Kong B; Zheng W
    J Hematol Oncol; 2013 Aug; 6():60. PubMed ID: 23958394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinosarcoma arising from high-grade serous carcinoma of the ovary without estrogen receptor, WT-1, and PAX8 immunoreactivity.
    Harada N; Nobuhara I; Haruta N; Higashiura Y; Fujii H; Yamao K; Shimada K
    Taiwan J Obstet Gynecol; 2022 Jan; 61(1):110-114. PubMed ID: 35181017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.